Avicanna (AVCN.TO) Stock Price

Avicanna Inc's business model revolves around the development and commercialization of pharmaceutical-grade cannabinoid-based products. The company focuses on harnessing the therapeutic potential of cannabinoids through research, collaboration, and strategic partnerships. Avicanna aims to offer innovative solutions for various medical conditions by leveraging their expertise in pharmaceutical development, cultivation, extraction, and formulation technologies. Their comprehensive portfolio includes patented and patent-pending pharmaceutical-grade formulations, derma-cosmetics, and natural health products. Avicanna Inc strives to revolutionize the global medical cannabis market by providing high-quality, evidence-based medicinal products to improve patients' lives.

Avicanna Inc is primarily active in the cannabis and pharmaceutical industries.

Avicanna Inc is a renowned Canadian biopharmaceutical company. Founded in 2016, Avicanna specializes in the development and commercialization of plant-derived cannabinoid-based products. With a mission to harness the therapeutic potential of cannabinoids, Avicanna leverages its scientific expertise in evidence-based research, pharmaceutical development, and cultivation techniques. The company operates globally and maintains partnerships with various academic institutions and multinational organizations to advance its innovations. Avicanna is recognized for its vertically integrated approach, ensuring quality control from cultivation to end products, which include pharmaceuticals, skincare, and nutraceuticals. With a commitment to scientific excellence, Avicanna remains at the forefront of the rapidly expanding cannabis industry.

Avicanna Inc has achieved several significant milestones in its history. Firstly, the company successfully attained a license from the Colombian government for the cultivation of psychoactive cannabis plants. In addition, Avicanna has established strategic partnerships with leading academic institutions, such as the University of Toronto, to conduct extensive scientific research on cannabinoids. The company has also developed several innovative pharmaceutical and dermacosmetic products, leveraging its expertise in cannabinoid-based therapies. Avicanna Inc has gained international recognition for its high-quality products and innovative research, positioning itself as a prominent player in the global cannabis industry.

Avicanna Inc is primarily present in Canada, Colombia, and Jamaica.

Avicanna Inc represents a strong commitment to innovation, integrity, and sustainability. With its focus on the development and commercialization of plant-derived pharmaceuticals, Avicanna aims to provide advanced medical solutions using cannabinoid-based therapies. The company's corporate philosophy is centered on rigorous scientific research, stringent quality control standards, and ethical practices throughout its operations. Avicanna's dedication to collaboration with healthcare professionals, regulatory compliance, and patient-centric care underscores its mission to enhance the lives of individuals with unmet medical needs. Through its pioneering efforts, Avicanna Inc strives to redefine the future of cannabinoid-based medicines.

9 analysts currently rate the Avicanna stock: 0 recommend buying, 2 holding and 7 selling. For 2026, analysts expect Avicanna to generate revenue of 35.01 M CAD and earnings per share of 0.00 CAD.

Avicanna Analyst Price Targets 2026

Converted at the current exchange rate, the Avicanna share trades at 0.07 EUR (0.10 CAD).

The Avicanna share (AVCN.TO) is listed on 4 stock exchanges, including: Toronto (AVCN.TO), Frankfurt (0NN.F), München (0NN.MU).

Avicanna Inc is a Canadian biotechnology company in the medical and recreational cannabis industry. The company is based in Toronto and focuses on researching, developing, and manufacturing plant-based products using cannabinoids. Avicanna aims to deliver innovative products to improve the lives of patients and consumers. The company currently has three main business divisions: medical products, cosmetic products, and recreational products. In the medical field, Avicanna focuses on producing medical cannabis products for the treatment of serious illnesses such as cancer, pain, and inflammation. The company has also developed products specifically designed for women with menstrual discomfort and for patients with insomnia. In addition to medical products, Avicanna has also developed a line of advanced skincare products based on cannabinoids, specifically designed for people with skin conditions. With products such as lotions, serums, and tinctures, customers in Avicanna's cosmetic division can utilize a natural alternative for skincare based on the healing properties of cannabis. In the recreational sector, Avicanna recognizes the growing demand for cannabis products and has therefore developed products for the recreational market. Avicanna's recreational products include smoked cannabis, edible products, beverages, and oils. These products are becoming increasingly popular in the cannabis industry and can be used by customers as a legal alternative to illicit drugs. Aside from its main business divisions, Avicanna has also formed partnerships and joint ventures with other companies to spread its technology and products throughout the industry. For example, a strategic partnership with Santa Marta Golden Hemp in Colombia will allow Avicanna to produce its products and technologies at a competitive cost base and enter the South American market. Avicanna's business model is to develop medical, cosmetic, and recreational cannabis products based on the natural healing properties of cannabis. The company aims to provide natural alternatives for diseases treatment and skincare, while also serving the rapidly evolving recreational cannabis industry. Avicanna also utilizes strategic partnerships to spread its technology and products within the cannabis industry.

The expected revenue of Avicanna is 35.01 M CAD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Avicanna is 268,970.90 CAD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Avicanna is currently 46.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Avicanna stock.

The price-to-sales ratio (P/S) of Avicanna is currently 0.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Avicanna stock.

The Eulerpool Quality Score for Avicanna is 4/10.

The ISIN of Avicanna is CA05368K1003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Avicanna is A2PN04. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Avicanna is AVCN.TO. The ticker symbol is used to trade Avicanna shares on the stock exchange.